Surge in Demand for Heart Valve Catheter Procedures.. Upgraded Forecast for Double-Digit Growth by 2026

Edwards Lifesciences Corp (EW), a cardiac valve therapy device maker, said fourth-quarter 2025 revenue rose more than 13% year-over-year to $1.57 billion (about ₩2 trillion), while full-year sales grew at an 11% rate, driven by strong performance in its TAVR and TMTT businesses. The company is targeting 8–10% revenue growth at constant exchange rates for 2026, TMTT revenue growth of 35–45%, and adjusted EPS of $2.90–$3.05, citing multiple clinical, regulatory and market milestones as growth catalysts. CEO Bernard Jovizian exercised stock options on February 12 at about $59 per share and sold a portion of his holdings in the low $70s for roughly $1.7 million (around ₩2 billion), though filings show he still retains a substantial stake.

On February 2, Edwards Lifesciences’ stock outperformed the S&P 500, snapping a four-day decline and demonstrating solid momentum. At its December 2025 annual investor meeting, the company reaffirmed its 2026 goals of 8–10% revenue growth and 35–45% annual TMTT growth, anchored by its structural heart disease portfolio.

Headquartered in California, Edwards Lifesciences is a global leader in structural heart disease, specializing in catheter-based aortic valve replacement (TAVR) and mitral and tricuspid valve therapies (TMTT). With an aging population and rising cardiovascular disease rates driving rapid expansion in minimally invasive cardiac procedures, suppliers of artificial heart valves and related catheter-based devices are poised for long-term growth.